Yesterday evening the FDA announced that Vilazodone, a novel combination SSRI/5HT1A receptor agonist antidepressant from Clinical Data (CLDA), received approval for marketing in the U.S. This is certainly cause for celebration among Clinical Data’s shareholders as this was a ‘first pass’ approval, a feat that is becoming rarer and rarer with today’s increasingly risk . . . → Read More: Clinical Data’s Vilazodone Approved!

Yesterday evening the FDA announced that Vilazodone, a novel combination SSRI/5HT1A receptor agonist antidepressant from Clinical Data (CLDA), received approval for marketing in the U.S. This is certainly cause for celebration among Clinical Data’s shareholders as this was a ‘first pass’ approval, a feat that is becoming rarer and rarer with today’s increasingly risk . . . → Read More: Clinical Data’s Vilazodone Approved!

After an exciting trading day than involved a suspected ‘bear raid’ and, not one, but two trading stops during the day, MannKind was issued a complete response letter (CRL) for its inhalable insulin therapy Afrezza. There was certainly a lot of hype leading up to the decision as news of the new therapy swept . . . → Read More: FDA Requests More Clinical Trials for MannKind’s Afrezza

Today, Depomed’s (DEPO) share price dipped mysteriously mid-day by over 10%. Upon market close, a press release was issued by Depomed potentially explaining the mysterious drop. Abbott is apparently convinced that they are not responsible for launching and commercializing Depomed’s DM-1796, an extended release form of gabapentin for the treatment of post-herpetic nueralgia.

I’ve . . . → Read More: Depomed “Puzzled” by Abbott’s Unwillingness to Launch DM-1796

A few updates you should be aware of, as it’s been a relatively eventful morning thus far.

KV Pharmaceuticals (KV.A)

Today KV Pharmaceuticals today announced that its PDUFA date for Gestiva, previously scheduled for January 13, has been pushed back to April 13. The delay was triggered by the submission of additional . . . → Read More: FDA Catalyst Updates

New Year New Money Making Link RoundUp

Here at Buy Like Buffett, the goal is to help you build wealth and make money investing the Warren Buffett Way. It’s a New Year which means it time for a new link roundup. These are the best articles online that will help show you different ways to make money. One Money Design says Shred [...]

My Blog Posts From Around The World Wide Web

Every now and again I do an update of my posts from around the world wide web. Here are a few of the posts that I have had published over the past week. Mark Riddix on How To Break Your Blog Out Of A Traffic Funk. Blonde and Balanced hosts The 289th Edition of the [...]

Have you ever wondered what make the stock market rise and fall? If you watch the news at all, you will have seen the stock market prices tumble into a deep red sea one day, while rising through the clouds the very next day. Why stock market prices behave in such a way is a [...]

Hey guys — I’ve been really busy with an examination this past week, so the time spent on updating the site was greatly reduced, however I am back! In this video I hope to unearth your interest in two really informative web sites which are essential in your “must have” book of stock market knowledge. [...]